Your browser doesn't support javascript.
loading
Seeding competent TDP-43 persists in human patient and mouse muscle.
Lynch, Eileen M; Pittman, Sara; Daw, Jil; Ikenaga, Chiseko; Chen, Sheng; Dhavale, Dhruva D; Jackrel, Meredith E; Ayala, Yuna M; Kotzbauer, Paul; Ly, Cindy V; Pestronk, Alan; Lloyd, Thomas E; Weihl, Conrad C.
Affiliation
  • Lynch EM; Department of Neurology, Washington University in St Louis; St Louis, MO, USA.
  • Pittman S; Department of Neurology, Washington University in St Louis; St Louis, MO, USA.
  • Daw J; Department of Neurology, Washington University in St Louis; St Louis, MO, USA.
  • Ikenaga C; Department of Neurology, Johns Hopkins University School of Medicine; Baltimore, MD, USA.
  • Chen S; Department of Chemistry, Washington University in St Louis; St Louis, MO, USA.
  • Dhavale DD; Department of Neurology, Washington University in St Louis; St Louis, MO, USA.
  • Jackrel ME; Department of Chemistry, Washington University in St Louis; St Louis, MO, USA.
  • Ayala YM; Department of Biochemistry and Molecular Biology, Saint Louis University; St Louis, MO, USA.
  • Kotzbauer P; Department of Neurology, Washington University in St Louis; St Louis, MO, USA.
  • Ly CV; Department of Neurology, Washington University in St Louis; St Louis, MO, USA.
  • Pestronk A; Department of Neurology, Washington University in St Louis; St Louis, MO, USA.
  • Lloyd TE; Department of Neurology, Baylor College of Medicine, Houston, TX, USA.
  • Weihl CC; Department of Neurology, Washington University in St Louis; St Louis, MO, USA.
bioRxiv ; 2024 Apr 04.
Article in En | MEDLINE | ID: mdl-38617354
ABSTRACT
TAR DNA-binding protein 43 (TDP-43) is an RNA binding protein that accumulates as aggregates in the central nervous system of some neurodegenerative diseases. However, TDP-43 aggregation is also a sensitive and specific pathologic feature found in a family of degenerative muscle diseases termed inclusion body myopathy (IBM). TDP-43 aggregates from ALS and FTD brain lysates may serve as self-templating aggregate seeds in vitro and in vivo, supporting a prion-like spread from cell to cell. Whether a similar process occurs in IBM patient muscle is not clear. We developed a mouse model of inducible, muscle-specific cytoplasmic localized TDP-43. These mice develop muscle weakness with robust accumulation of insoluble and phosphorylated sarcoplasmic TDP-43, leading to eosinophilic inclusions, altered proteostasis and changes in TDP-43-related RNA processing that resolve with the removal of doxycycline. Skeletal muscle lysates from these mice also have seeding competent TDP-43, as determined by a FRET-based biosensor, that persists for weeks upon resolution of TDP-43 aggregate pathology. Human muscle biopsies with TDP-43 pathology also contain TDP-43 aggregate seeds. Using lysates from muscle biopsies of patients with IBM, IMNM and ALS we found that TDP-43 seeding capacity was specific to IBM. Surprisingly, TDP-43 seeding capacity anti-correlated with TDP-43 aggregate and vacuole abundance. These data support that TDP-43 aggregate seeds are present in IBM skeletal muscle and represent a unique TDP-43 pathogenic species not previously appreciated in human muscle disease.

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: BioRxiv Year: 2024 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: BioRxiv Year: 2024 Document type: Article Affiliation country: Country of publication: